Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG..
Non-alcoholic fatty liver disease (NAFLD) is a multifaceted disease allied with various metabolic disorders, obesity and dysbiosis. Gut microbiota plays an influential role in the pathogenesis of NAFLD and other metabolic disorders. However, recent scientific upsurge emphasizes on the utility of beneficial gut microbiota and bacteriotherapy in the management of NAFLD. Fecal microbiota transplantation (FMT) is the contemporary therapeutic approach with state-of-the-art methods for the treatment of NAFLD. Other potential therapies include probiotics and prebiotics supplements which are based on alteration of gut microbes to treat NAFLD. In this review, our major focus is on the pathological association of gut microbiota with progression of NAFLD, historical aspects and recent advances in FMT with possible intervention to combat NAFLD and its associated metabolic dysfunctions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Inflammation research : official journal of the European Histamine Research Society ... [et al. - 70(2021), 7 vom: 02. Juli, Seite 765-776 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gupta, Manisha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fecal microbiota transplantation (FMT) |
|---|
| Anmerkungen: |
Date Completed 05.01.2022 Date Revised 05.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00011-021-01480-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327589213 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327589213 | ||
| 003 | DE-627 | ||
| 005 | 20231225201120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00011-021-01480-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1091.xml |
| 035 | |a (DE-627)NLM327589213 | ||
| 035 | |a (NLM)34212214 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gupta, Manisha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2022 | ||
| 500 | |a Date Revised 05.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG. | ||
| 520 | |a Non-alcoholic fatty liver disease (NAFLD) is a multifaceted disease allied with various metabolic disorders, obesity and dysbiosis. Gut microbiota plays an influential role in the pathogenesis of NAFLD and other metabolic disorders. However, recent scientific upsurge emphasizes on the utility of beneficial gut microbiota and bacteriotherapy in the management of NAFLD. Fecal microbiota transplantation (FMT) is the contemporary therapeutic approach with state-of-the-art methods for the treatment of NAFLD. Other potential therapies include probiotics and prebiotics supplements which are based on alteration of gut microbes to treat NAFLD. In this review, our major focus is on the pathological association of gut microbiota with progression of NAFLD, historical aspects and recent advances in FMT with possible intervention to combat NAFLD and its associated metabolic dysfunctions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Fecal microbiota transplantation (FMT) | |
| 650 | 4 | |a Gut microbiota | |
| 650 | 4 | |a Non-alcoholic fatty liver diseases (NAFLD) | |
| 650 | 4 | |a Non-alcoholic steatohepatitis (NASH) | |
| 700 | 1 | |a Krishan, Pawan |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Amarjot |e verfasserin |4 aut | |
| 700 | 1 | |a Arora, Sandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Trehanpati, Nirupma |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Thakur Gurjeet |e verfasserin |4 aut | |
| 700 | 1 | |a Bedi, Onkar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammation research : official journal of the European Histamine Research Society ... [et al. |d 1997 |g 70(2021), 7 vom: 02. Juli, Seite 765-776 |w (DE-627)NLM075208601 |x 1420-908X |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2021 |g number:7 |g day:02 |g month:07 |g pages:765-776 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00011-021-01480-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2021 |e 7 |b 02 |c 07 |h 765-776 | ||